Published by Michele Maatouk on 12th October 2018
(Sharecast News) - Chemring tumbled on Friday as Barclays cut its stance on the stock to 'underweight' from 'equalweight' and chopped the target price to 185p from 258p as it said company-gathered consensus is "materially" outdated after the Salisbury fatality in August and the premium valuation is unjustified.